CD4 and lung cancer: For instance, a study by Adusumilli et al56 showed that the therapeutic efficacy of MSLN‐CAR‐T therapy for lung cancer was dependent on early CD4+T cell activation and CD4+T cell‐mediated cytotoxicity, but not CD8+T cells.